Кардиоваскулярная терапия и профилактика (Dec 2009)

Clinical effectiveness of long-term trimetazidine MB therapy in patients with cardio-respiratory disease (the results of an open, prospective multi-centre study)

  • N. M. Kolomoets,
  • V. I. Baksheev,
  • E. G. Zarubina,
  • K. U. Uvaysova,
  • A. V. Pleshakov

Journal volume & issue
Vol. 8, no. 6
pp. 21 – 28

Abstract

Read online

Aim. To study the prevalence and clinical features of cardio-respiratory disease (CRD): coronary heart disease (CHD) + chronic obstructive pulmonary disease (COPD). To assess the long-term effectiveness of a myocardial cytoprotector, trimetazidine MB, as a part of complex therapy.Material and methods. The retrospective analysis of 2446 medical histories assessed CRD prevalence and clinical features. The subjects were randomised into two groups: Group I (135 patients with CHD and severe COPD) and Group II (96 individuals with CHD and moderate COPD). Group I was administered trimetazidine MB (70 mg/d) for one year. Control assessments took place every three months.Results. CRD was more prevalent in elderly CHD patients (56,7%). The combination of CHD and COPD was characterized by higher risk of Q-wave myocardial infarction (MI), unstable angina, complex arrhythmias, and early CHD progression, and increased time of silent myocardial ischemia. After one year of trimetazidine MB treatment, Group I demonstrated a significant decrease in angina episode incidence and silent myocardial ischemia time (p<0,05); in 64,4% of the patients, regression of cardiac symptoms and extrasystolia incidence were also observed.Conclusion. Long-term trimetazidine MB therapy, as a part of complex treatment, normalised cardiovascular parameters, reduced complication risk, and improved prognosis in CRD patients, without any substantial adverse effects.

Keywords